WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will present new data on its investigational oncolytic peptide therapy, VP-315, for the treatment of basal cell carcinoma (BCC) at the upcoming Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, scheduled for November 5–9, 2025, in National Harbor, Maryland.
The company will deliver both an oral and poster presentation focused on exploratory analyses from its Phase 2 multicenter study evaluating immune activation within the tumor microenvironment following VP-315 treatment. The abstract will be available on the SITC website beginning November 4, 2025, at 9 a.m. ET.
Kenneth Y. Tsai, MD, PhD, Vice Chair of Research at the Moffitt Cancer Center and Co-Director of its Melanoma and Skin Cancer Center of Excellence, will present the findings during the “Rapid Oral Abstract Session – Clinical” on November 7. The oral presentation will explore tumor-specific immune responses observed 12 weeks after VP-315 administration.
A corresponding poster session will feature contributions from multiple clinical investigators and Verrica researchers, detailing data that support VP-315’s mechanism of action and its potential role as a non-surgical treatment option for patients with basal cell carcinoma.
VP-315 is a first-in-class oncolytic chemotherapeutic peptide immunotherapy designed to trigger immunogenic cell death within tumors, exposing a wide range of tumor antigens and initiating T-cell responses. The therapy is administered directly into tumors and has demonstrated promising immune activation in earlier clinical studies.
Verrica holds exclusive global rights to develop and commercialize VP-315 across select dermatologic oncology indications, including basal cell carcinoma, squamous cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. The company continues to prioritize BCC and squamous cell carcinoma as its lead indications as it advances VP-315 through clinical development.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.